Akèy › Kansè Poumon ki pa ti selil › Virginia
Etid klinik pou Kansè Poumon ki pa ti selil nan Virginia
137 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
- Arlington104 etid
- Richmond25 etid
- Charlottesville21 etid
- Alexandria11 etid
- Roanoke8 etid
- Norfolk7 etid
- Winchester6 etid
- Fredericksburg5 etid
- Lynchburg4 etid
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Ballad Health Cancer Care - Bristol, Bristol
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- ak 7 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Virginia Cancer Specialists ( Site 0167), Fairfax
- Virginia Oncology Associates (VOA) ( Site 8101), Norfolk
- VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06623422The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Blue Ridge Cancer Center, Blacksburg
- Virginia Cancer Specialists, PC, Fairfax
- Shenandoah Oncology P.C., Winchester
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07365319A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #66, Charlottesville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Hematology Oncology Associates of Fredericksburg ( Site 3275), Fredericksburg
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07513376A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Virginia Cancer Specialists ( Site 0114), Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07554339A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Hematology Oncology Associates of Fredericksburg ( Site 9550), Fredericksburg
- Blue Ridge Cancer Care ( Site 0144), Roanoke
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- Virginia Cancer Institute, Richmond
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 2, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Blue Ridge Cancer Care, Christiansburg
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361497A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0337, Richmond
- Shenandoah Oncology, P.C., Winchester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361510A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07659782Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06765109Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Virgnia Cancer Specialists /ID# 269633, Leesburg
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07127874A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Oncology & Hematology Associates of Southwest Virginia,Inc.DBA Blue Ridge Cancer Care, Blacksburg
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer care| Emmett Medical & Surgical Center, Low Moor
- VCU Emergency Center at New Kent, Quinton
- ak 12 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05498428Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07222566A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07227025A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Stony Point, Richmond
- ak 4 plis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07227298Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- University of Virginia Health System, Charlottesville
- VCU Health Adult Outpatient Pavillion, Richmond
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Virginia Cancer Institute, Richmond
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- University of Virginia Cancer Center, Charlottesville
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Fort Belvoir
- Research Site, Leesburg
- Research Site, Midlothian
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06357533A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Virginia Cancer Specialists PC, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07140016Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Fairfax
Ap rekriteFaz 2
Laj 18 a 95 · Tout sèks · Mizajou Sep 23, 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax
- VCU Massey Cancer Center, Richmond
- ak 1 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06568939A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Inova Schar Cancer Institute Clinical Trials, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07488676Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University of Virginia Health System, Charlottesville
- Virginia Commonwealth University (Vcu), Richmond
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07100080Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Next Oncology Virginia Cancer Specialist, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Fairfax
- Research Site, Fredericksburg
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Blacksburg
- Clinical Study Site, Charlottesville
- Clinical Study Site, Fairfax
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.